outlook posit
revenu pcp cc beat bofaml consensu non
point strong perform across product geographi
top-line growth exclud acquisit ii mask standout us row cc
success mask launch improv adher rate iii saa high singl
digit organ growth iv us devic row cc japan franc complet
upgrad program bpt margin expans matrixcar contribut
manufacturing/procur effici remaind
remain bullish reiter buy rate increas po per
assumpt rais us row mask growth rate reflect
result vs previous deliv mask growth
row despit launch fph new vitera mask key row market expect
hold posit mask competitor launch broader rang mask
and/or step market activ ii revis gross margin anticip
improv margin flat matrixcar lap one
year mileston acquisit iii rais us devic growth rate
previous iii saa expect achiev doubl digit saa growth end
line forecast organ growth
point note less impact us/china tariff philip given
manufactur locat ii dme bid submit last month
support dme assist understand chang process
full definit iqmethod sm measur see page
employ non-u affili bofa registered/qualifi research analyst
finra rule
refer import disclosur inform certain bofa merril lynch entiti take
respons inform herein particular jurisdict
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt naa
outsid equiti interest npat
chang work capit
 flow item int tax
 flow oper
oper
acquisit dispos invest
 flow invest
invest
 flow financ
financ
return capit employ
return equiti
iqmethod sm qualiti earn
full definit iqmethod sm measur see page
lead develop
manufactur medic devic mask cloud-
base softwar applic diagnos treat
manag respiratori disord headquart
san diego california focuss
connect health deliv better outcom
sleep apnea chronic obstruct pulmonari
outpac industri growth
market share place
everi market oper benefit
clinic data-captur proprietari
softwar boost therapi complianc
rate increas mask accessori growth
addit market develop
market activ target
moder sever osa suffer world-wide
price book valu
tabl result comparison
 revenue
sg revenue
tabl product revenu geograph region
gross prof
oper prof
 revenue
sg revenue
price object per share base dcf
valuat dcf use wacc termin growth rate beta
downsid risk po loss momentum saa busi market
educ effort achiev expect revenu growth reimburs
chang health ministri phi poor recept new product launch
technolog advanc competitor product fx chang
lyann harrison herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
qualiti earn
